Healthcare Equipment and Supplies
Company Overview of Dune Medical Devices Corporation
Dune Medical Devices Corporation develops a tissue characterization technology that enables surgeons and radiologists to detect cancer in real-time. It offers MarginProbe System, a technology that detects cancer by assessing the electromagnetic response of tissue, as well as delivers real-time assessment on excised tissue in breast cancer surgery. The company was founded in 2002 and is based in Caesarea, Israel. It also has offices in Boston and Framingham, Massachusetts; Israel; and Switzerland.
20 Alon Hatavor Street
Industrial Park South
Founded in 2002
Key Executives for Dune Medical Devices Corporation
Chief Executive Officer and Director
Founder, President, Chief Technology Officer and Director
Vice President of Finance & Administration
Vice President of Research, Development and Engineering
Compensation as of Fiscal Year 2014.
Dune Medical Devices Corporation Key Developments
Dune Medical Devices Announces FDA Approval of Updated Version of MarginProbe
Jan 5 15
Dune Medical Devices announced FDA approval of an updated version of its product, MarginProbe, a medical device that enables real-time detection of cancer at the surface of excised tissue specimens during breast-conserving cancer surgery. Surgeon feedback, innovative design ideas, and superior miniaturization engineering were the driving forces behind the development of MarginProbe 1.2. This new version, which utilizes the same trusted, FDA-approved, diagnostic technology as version 1.1, is focused on proving superior functionality, portability, and overall ease of use. Feature enhancements for MarginProbe 1.2 include: onReduced Size & Weight: A major highlight of MarginProbe 1.2 is the reduced size. The new unit is in tabletop form (29 x 43 x 38 cm in size) and weighs 35 lbs. making it 75% lighter and much easier to handle in busy operating rooms. onBrighter Screen: The screen's brightness has been enhanced to provide surgeons a clearer screen image. onWider Viewing angle: With MarginProbe 1.2, surgeons will have the ability to clearly view the screen from anywhere in the operating room without encountering a glare, pixilation, or a blind spot. onImproved on-screen notices: Ensuring key alerts are easier to notice in the OR ambiance. onStartup Time Reduced 50%: The startup time for MarginProbe 1.2 is reduced from approximately three minutes to 90 seconds, making MarginProbe's services even more instantaneous. onImproved service time: Due to its new reduced size, technicians are able to provide faster service, reducing down time in case service is needed.
Dune Medical Devices Corporation' MarginProbe System Available in the United States
Mar 19 13
Dune Medical Devices Corporation announced the MarginProbe System, a breakthrough intra-operative tissue assessment device used during lumpectomy surgery to treat early-stage breast cancer, is now available to patients in the United States, with the installation of the first System at University of California, Irvine Medical Center. Dune Medical Devices will be rolling out the MarginProbe System to additional hospitals across the U.S. in the coming months. The MarginProbe System, which received premarket approval from the US Food and Drug Administration on December 27, 2012, significantly improves surgeons' ability to intra-operatively identify 'cancer on the margin' and significantly reduce pathologically positive margins following a patient's initial lumpectomy surgery.
Dune Medical Devices Corporation Announces Results from the Pivotal Clinical Trial for the Marginprobe System
Mar 7 13
Dune Medical Devices Corporation announced that results from the pivotal clinical trial for the MarginProbe System, Dune's breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, were presented at the 66th Annual Society of Surgical Oncology (SSO) Cancer Symposium. FDA approval of the MarginProbe System was based on a 664 patient prospective, multi-center, randomized, double arm study to evaluate the effectiveness of MarginProbe System in identifying cancerous tissue along the margins of removed breast tissue during initial lumpectomy procedures. The MarginProbe System, which uses electromagnetic "signatures" to identify healthy and cancerous tissue, was found to be over three times more effective in finding cancer on the margin during lumpectomy, compared to traditional intra-operative imaging and palpation assessment. This enabled surgeons to significantly reduce the number of patients with positive margins following initial surgery.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 26, 2014